Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Grijalva CG, et al. Among authors: delzell e. JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6. JAMA. 2011. PMID: 22056398 Free PMC article.
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchel EF Jr, Stein CM, Griffin MR. Kawai VK, et al. Among authors: delzell e. Arthritis Care Res (Hoboken). 2011 Oct;63(10):1415-24. doi: 10.1002/acr.20550. Arthritis Care Res (Hoboken). 2011. PMID: 22121511 Free PMC article.
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. Curtis JR, et al. Among authors: delzell e. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805. Arthritis Care Res (Hoboken). 2012. PMID: 22833479 Free PMC article.
Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.
Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchell EF Jr, Stein CM, Griffin MR. Kawai VK, et al. Among authors: delzell e. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1085-94. doi: 10.1002/acr.21937. Arthritis Care Res (Hoboken). 2013. PMID: 23281339 Free PMC article.
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Baddley JW, et al. Among authors: delzell e. Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407. Epub 2013 Jul 13. Ann Rheum Dis. 2014. PMID: 23852763 Free PMC article.
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E, Patkar N, Rassen J, Winthrop KL, Nourjah P, Saag KG. Herrinton LJ, et al. Among authors: delzell e. Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1199-209. doi: 10.1002/pds.2196. Epub 2011 Sep 15. Pharmacoepidemiol Drug Saf. 2011. PMID: 21919113 Free PMC article.
210 results